Chronic Heart Failure Drug Sales Expected to Increase
New forecasts published by Decision Resources show an expected increase in the sales of medicines to treat chronic heart failure. The forecasts show growth from around $2.9 billion in 2013 to an expected $8.9 billion in 2023.
Growth in seven main markets (US, UK, France, Germany, Italy, Spain and Japan) will be driven mainly by the introduction of Novartis’ LCZ-696, a first-in-class dual angiotensin II receptor antagonist (AIIRA)/neprilysin inhibitor. LCZ-696 is expected to launch in the second half of 2015 and could add almost $4 billion in yearly sales in 2023, according to the forecasts, from Decision Resources.
LCZ-696 is expected to revolutionise treatment for Chronic Heart Failure (CHF) after positive results from the PARADIGM-HF study. “This exciting new agent represents a step up from past and present agents in development for CHF in that it could replace the standard of care for many CHF patients,” Decision Resources group analyst, Joseph Dwyer, commented.
However, the study notes that Novartis is expected to face a number of obstacles with the launch of the drug, a major hurdle being its expected high price compared to generically-available CHF agents.
A number of other treatments are also expected to launch to treat Chronic Heart Failure during the 10-year forecast period. These treatments include Novartis’ Tekturna/Rasilez, Bayer’s finerenone and Xarelto, Teva/Mesoblast’s CEP-41750, and Celladon’s genetically-targeted enzyme replacement therapy Mydicar. These treatments combined could result in sales of almost $2 billion among the seven main markets in 2023, claims the Decision Resources’ report.
Additionally, Decision Resources expect Servier’s Procoralan to be launched in both the US and Japan during the forecast period.